Biocon, Amylin Pharmaceuticals in Deal for Peptide Hybrid

Biopharmaceutical company Amylin Pharmaceuticals (San Diego, CA) and biotechnology firm Biocon (Bangalore, India) say they have entered into an exclusive agreement to jointly develop, manufacture, and commercialize a novel peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon will collaborate to develop the therapeutic potential of the compound and share development costs. Amylin will provide expertise in peptide hormone development as well as metabolic disease therapeutics, and Biocon will utilize its expertise in recombinant microbial...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers